Adenosine: The prototypic neuromodulator

Neurochemistry International

Volumn 14, Issue 3, 1989, Pages 249-264

  Williams, Michael ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE; ADENOSINE RECEPTOR; CYCLIC AMP; RECEPTOR SUBTYPE;

ANIMAL CELL; NEUROMODULATOR; NONHUMAN; PRIORITY JOURNAL; REVIEW;

EID: 0024537435     PISSN: 01970186     EISSN: None     Source Type: Journal    
DOI: 10.1016/0197-0186(89)90051-X     Document Type: Article

References (210)

1. Changes in adenosine receptor sensitivity in morphine-tolerant and -dependent mice
2. Modification of the anticonvulsant efficacy of diazepam by Ro 15–1788 in the kindled amygdaloid seizure model
3. 3H]cyclohexyladenosine, to rat hypothalamus
4. The control of the metabolism and the hormonal role of adenosine
5. Methylxanthines in apnea of prematurity
6. Identification of inosine and hypoxanthine as endogenous ligands for brain benzodiazepine binding sites
7. Energy charge of the adenylate pool as a regulatory parameter
8. 2 via GTP-binding proteins: arachidonic acid and its metabolites as second messengers
9. Supply-to-demand ratio for oxygen determines formation of adenosine by the heart
10. Adenosinergic modulation of brain-stem mechanisms involved in cardiovascular control
11. Dissociation of locomotor and hypotensive effects of adenosine analogues in rat
12. Chronotropic and dromotropic actions of adenosine
13. Cardiac nucleotides in hypoxia—possible role in regulation of coronary flow
14. Release of adenosine from ischemic brain
15. Adenosine in the local regulation of blood flow: a brief overview
16. Adenosine-induced immunosuppression: the role of the adenosine receptor-adenylate cyclase interaction in the alteration of T-lymphocyte surface phenotype and immunoregulatory function
17. Pharmacological modification of immunoregulatory T-lymphocytes: II. Modulation of T-cell surface characteristics
18. The OKT4 + Leu8 + T-cell in adenosine induced immunosuppression
19. Adenosine containing neurons in the brain localized by immunocytochemistry
20. 6-[2(3,5-dimethoxyphenyl-2-(2-methylphenyl)-ethyl]adenosine and its uronamide derivatives
21. 3H]NECA in rat striatal membranes
22. Adenosine receptor interactions and anxiolytics
23. Adenosine antagonists as pharmacological tools
24. 1 selective adenosine antagonist 8-cyclopentyl-1,3-dipropylxanthine to ratbrain membranes
25. A basis for distinguishing two types of purinergic receptor
26. Neurochemical control of blood vessels: some future directions
27. A potent non-peptide cholecystokinin antagonist selective for peripheral tissues isolated from Aspergillus alliaceus
28. Increased anxiogenic effects of caffeine in panic disorders
29. Specific photoaffinity labeling of inhibitory adenosine receptors
30. Adenosine and asthma
31. 2-receptor mediated mechanism
32. Adenosine and renal function
33. Mediation of acute ethanol-induced motor disturbances by cerebellar adenosine in rats
34. Modulation of atrioventricular node transmission by adenosine in hypoxic isolated guinea pig hearts
35. Character and meaning of quasi-morphine withdrawal phenomena elicited by methylxanthines
36. Signal transduction mechanisms for adenosine
37. Assessment of purine-dopamine interactions in 6-hydroxy-dopamine lesioned animals: evidence for presynaptic and postsynaptic influences by adenosine
38. Adenosine and immune function
39. Adenosine: a physiological modulator of superoxide anion generation by human neutrophils
40. CGS 8216: receptor binding characterization of a potent benzodiazepine antagonist
41. Adenosine receptors: target sites for drugs
42. Adenosine receptors in the central nervous system: structure activity relationships for agonists and antagonists
43. Subclasses of adenosine receptor in the central nervous system: interaction with caffeine and related methylxanthines
44. Possible role of adenosine in the CNS effects of ethanol in mice
45. Pyrazolo[3,4-d]pyrimidines as adenosine antagonists
46. 3 cells via a pertussis sensitive mechanism
47. 2 adenosine receptors in spinal mechanisms of nocioception
48. Adenosine: electrophysiologic effects and therapeutic use for terminating paroxysmal supraventricular tachycardia
49. An adenosine agonist inhibits and a cyclic AMP analogue enhances the release of glutamate but not GABA from slices of rat dentate gyrus
50. Purinergic mechanisms in epilepsy
51. Is adenosine an endogenous anticonvulsant?
52. The physiological activity of adenine compounds with especial reference to their action upon the mammalian heart
53. The physiological role of adenosine in the central nervous system
54. Sedative and anticonvulsant effects of adenosine analogs in mouse and rat
55. Role of adenosine in the regulation of breathing
56. Consequences of activation and adenosine-mediated inhibition of granulocytes during myocardial ischemia
57. Design of potent, orally effective, nonpeptide antagonists of the hormone cholecystokinin
58. Adenosine receptors mediating cardiac depression
59. An adenosine analogue, 2-chloroadenosine protects against long term development of ischemic cell loss in the rat hippocampus
60. A caffeine analogue (1,3,7-trimethyl-6-thioxo-2-oxopurine) with negative chronotropic and inotropic effects
61. Adenosine A1 receptors in mammalian brain: species differences in their interactions with agonists and antagonists
62. Structure-activity profile of a series of novel trazoloquinazoline adenosine antagonists
63. How does adenosine inhibit transmitter release?
64. 1-receptor agonists
65. Morphine increases depolarization induced purine release from rat cortical slices
66. On the mechanism by which methylxanthines enhance apomorphine induced rotational behavior in the rat
67. Adenosine receptors mediating cyclic AMP production in the rat hippocampus
68. Action of caffeine and theophylline on supersensitive dopamine receptors: considerable enhancement of receptor responses to treatment with dopa and dopamine
69. Neuropharmacology of 3-isobutylmethylxanthine:effects on central noradrenergic systems in vivo
70. Solubilized adenosine receptors in the brain: regulation by guanine nucleotides
71. Adenosine receptor activation in brain reduces stress-induced ulcer formation
72. Formation of adenosine by vascular endothelium: a homeostatic and antithrombogenic mechanism?
73. Attenuation of coronary reactive hyperemia with increasing interstitial theophylline permeation
74. Adenosine reduces cortical neuronal injury induced by oxygen or glucose deprivation
75. 3H]cyclohexyladenosine
76. Adenosine receptors. Autoradiographic evidence for their location on axon terminals of excitatory neurons
77. Ethanol regulation of adenosine receptor-stimulated cAMP levels in a clonal neural cell line: an in vitro model of cellular tolerance to ethanol
78. Antagonism of morphine analgesia by adenine, adenosine and adenine nucleotides
79. Nomenclature and classification of receptors and binding sites: the need for harmony
80. Differential effects of methylxanthines on local cerebral blood flow and glucose utilization in the conscious rat
81. Purine enzyme inhibition fails to alter benzodiazepine receptor binding in brain
82. Recent advances in the molecular pharmacology of benzodiazepine receptors and in the structure activity relationships of their agonists and antagonists
83. Extracellular adenosine, inosine, hypoxanthine, and xanthine in relation to tissue nucleotides and purines in rat striatum during transient ischemia
84. Synthesis and structure-activity relationships of pyrazolo[3,3-d]pyrimidin-7-ones as adenosine receptor antagonists
85. Correlation of adenosine receptor affinities and cardiovascular activity
86. Synthesis of xanthines as adenosine antagonists, a practical quantitative structure-activity relationship application
87. Nomenclature of adenosine receptors
88. 3H-noradrenaline from slices of rat brain neocortex
89. Inhibition of adenylate cyclase by adenosine analogues in preparations of broken and intact human platelets. Evidence for a unidirectional control of platelet function
90. Effects of theophylline on adenosine-induced respiratory depression in the preterm rabbit
91. Regulation of breathing in the rat: indications for a role for central adenosine mechanisms
92. Antipsychotic-like effects of adenosine receptor agonists
93. Caffeine is an intensifier of stress-indirect hormonal and pathophysiologic changes in mice
94. Studies on the adenosine receptor mediating the augmentation of histamine induced inositol phospholipid hydrolysis in guinea-pig cerebral cortex
95. Effect of cyclic 3′5′-adenosine monophosphate and theophylline on lymphocyte transformation
96. Cyclic adenosine monophosphate antagonism of morphine analgesia
97. the bronchoconstrictor activity of adenosine in asthma
98. The action of adenosine upon the human heart
99. Possible role of adenosine in macula densa mechanism of renin release in rabbits
100. 3H]NECA binding in rat brain tissue sections
101. 1, NMDA and PCP receptors in gerbil brain
102. Cyclic nucleotides and aminophylline produce different effects of nocioceptive and sensory responses in the rat spinal cord
103. The effect of electrical stimulation upon the accumulation of adenosine 3′5′-phosphate in isolated cerebral tissue
104. Effect of adenosine on the formation of prostacyclin in the rabbit isolated heart
105. 1 adenosine receptors
106. 1 adenosine receptors
107. 1 adenosine receptor from rat brain membranes
108. Chimergic α2,β2 adrenergic receptors: delineation of domains involved in effector coupling and ligand binding specificity
109. Neuroregulatory and neuropathological actions of the ether-phospholipid platelet activating factor
110. Platelet activating factor-induced aggregation of human platelets specifically inhibited by triazolobenzodiazepines
111. 14C]adenine derivatives newly formed in cerebral tissues and the effects of electrical stimulation
112. 14C]adenine derivatives at beds of mammalian cortical synaptosomes in a superfusion system
113. Adenosine analogues depress ventilation in rabbit neonates
114. 2 receptors on human monocytes modulate C2 production
115. Caffeine as an analgesic adjuvant
116. Excitatory amino acids and mammalian CNS function
117. Biochemical evidence of dysfunction of brain neurotransmitters in Lesch-Nyhan syndrome
118. 1 adenosine receptors
119. 1 adenosine receptors
120. Two distinct adenosine-sensitive sites on adenylate cyclase
121. Adenosine stimulates glycogenolysis in mouse cerebral cortex: a possible coupling mechanism between neuronal activity and energy metabolism
122. Purinergic inhibition of diazepam binding to rat brain (in vitro)
123. Specific and potent interactions of carbamazepine with brain adenosine receptors
124. Adenosine receptors on human basophils: modulation of histamine release
125. Characterisation of a specific adenosine receptor on human lymphocytes
126. Regulatory significance of the release and action of adenine derivatives in cerebral systems
127. Synaptic mediation and the structuring of cerebral activity
128. Differences in the biophysical properties of the benzodiazepine/γ-aminobutyric acid receptor chloride channel complex in the long-sleep and short-sleep mouse lines
129. Lesch-Nyhan syndrome, caffeine model: increase of purine and pyrimidine enzymes in rat brain
130. Ventilatory effects of adenosine mediated by carotid body chemoreceptors in the rat
131. Antagonism of 2-chloroadenosine induced respiratory depression by aminophylline and naloxone
132. Myocardial-ischemia-reperfusion injury: role of neutrophils and neutrophil derived mediators
133. Pharmacologic control of pemoline self injurious behavior in rats
134. 1 receptor binding in brain tissue
135. Effects of adenosine receptor agonists in the isolated, perfused rat kidney
136. Immunohistochemistry of adenosine deaminase: implication for adenosine neurotransmission
137. Adenosine and the concept of ‘retaliatory metabolites’
138. 2 adenosine receptor systems in the rat brain
139. Differential inhibition of lymphocyte function by 2-chloroadenosine
140. Effect of inhibition of purine enzymes on benzodiazepine binding in the human brain
141. 2 receptors of adenosine agonists and antagonists and their effects on heart rate and coronary vascular tone
142. The cardiovascular effects of xanthines in man
143. The role of adenosine in the regulation of glomerular filtration rate and renin secretion
144. Effects of enprofylline and theophylline may show the role of adenosine
145. Adenosine receptor agonists inhibit inositol phosphate accumulation in rat striatal slices
146. Adenosine's role in the central actions of the benzodiazepines
147. The role of adenosine in cerebral vascular regulation during reduction in perfusion pressure
148. The role of adenosine in the central actions of the benzodiazepines
149. The role of adenosine and its nucleotides in central synaptic neurotransmission
150. Pharmacological modification of immunoregulatory activity of lymphocytes: facts and potential
151. Adenosine receptors: immunologic aspects
152. Behavioral sensitivity to purinergic drugs parallels ethanol sensitivity in selectively bred mice
153. Adenine derivatives as neurohumoral agents in the brain
154. Adenosine attenuation of the electrophysiological effects of isoproterenol on canine cardiac Purkinje fibers
155. Biochemical and autoradiographic approaches to the characterization of adenosine receptors in the brain
156. Effect of adenosine on carotid chemoreceptor activity in the rat
157. 3) adenosine receptor
158. The actions of adenosine on respiration
159. Action of caffeine and aminophylline as respiratory stimulants in man
160. Benzodiazepine interactions with central thyroid-releasing hormone (TRH) binding sites: characterization and physiological significance
161. Chronic caffeine or theophylline exposure reduces γ-aminobutyric acid/benzodiazepine receptor site interactions
162. Tifluadom, an opiod benzodiazepine
163. Prolonged postictal depression in amygdaloid kindled rats of the adenosine analog, l-PIA
164. On some points in the treatment and clinical history of asthma
165. Inhibition of antibody production by 2-chloroadenosine
166. Regulation of thymocyte proliferation by endogenous adenosine and adenosine deaminase
167. The effect of adenosine and adenine nucleotides on the cyclic adenosine 3′,5′ phosphate content of guinea pig cerebral cortex slices
168. Biochemical and electrophysiological studies with tricyclic antidepressants in rat and guinea pig cerebral cortex
169. A protocol for molecular genetic neuroscience
170. Differential effect of adenosine on pre- and postsynaptic calcium fluxes
171. 3,7-Dimethyl-1-proparglyxanthine: a potent and selective in vivo antagonist of adenosine analogs
172. Modulation of receptors for thyrotropin-releasing hormoneby benzodiazepines: brain regional differences
173. 1 receptors in rat tissues
174. Adenosine as a neuromodulator
175. Adenosine receptors and behavioral actions of methylxanthines
176. Cardiovascular effects of adenosine in man; possible clinical implications
177. Regulation of adenosine formation by the heart
178. 1 adenosine receptor
179. A new high affinity, iodinated adenosine receptor antagonist as a radioligand/photoaffinity crosslinking probe
180. 1 adenosine receptor: identification of the binding subunit by photoaffinity cross-linking
181. Species differences in high affinity adenosine A-2 receptor binding in mammalian striatal membranes
182. Interactions of adenosine with other agents
183. Adenosine release
184. The role of xanthines in the management of asthma
185. 1 receptor selective adenosine antagonists
186. 2 receptors
187. Effect of aminophylline on muscle relaxant action of diazepam and phenobarbitone in genetically spastic rats: further evidence for a purinergic mechanism in the action of diazepam
188. Analogs of caffeine with selectivity for A-2 adenosine receptors
189. Development of stress-induced gastric lesions involves central adenosine A1-receptor stimulation
190. Adenosine regulates via two different types of receptors, the accumulation of cyclic AMP in cultured brain cells
191. An antiarrhythmic effect of adenosine during myocardial ischemia and reperfusion
192. Immunodeficiency diseases: primary and acquired
193. The renal response to atriopeptin III: antagonism by benzodiazepine receptor ligands
194. The negative chronotropic effect of adenosine in sinus node cells
195. Peptide mapping studies on muscarinic receptors: receptor structure and location of the ligand binding site
196. Anxioselective anxiolytics
197. Adenosine—a selective neuromodular in the mammalian CNS?
198. Purine receptors in mammalian tissue: pharmacology and functional significance
199. Adenosine antagonists
200. Adenosine antagonists as potential therapeutic agents
201. Interaction of the benzodiazepine antagonists Cls 8218 and Ro 15–1788 with central adenosine A-1 receptors
202. Interaction of putative anxiolytic agents with central adenosine receptors
203. 1 radioligand binding in rat cortex
204. Biochemical characterization of the triazoloquinazoline, CGS 15943, a novel non-xanthine adenosine antagonist
205. Inhibition of lymphocyte-mediated cytolysis by adenosine analogs: biochemical studies concerning mechanism of action